Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Investigators suggested that given both treatment-related harms and benefits, immune checkpoint inhibitor (ICI) + chemotherapy use in the first SACT setting requires informed decision-making; the potential benefits of ICI + chemotherapy vs single ICI in high-risk subgroups is encouraging.